LivaNova
LivaNova plc is a global medical technology company that designs, develops, and distributes cardiovascular and neuromodulation therapy solutions. The company operates through two primary business segments: Neuromodulation, featuring implantable vagus nerve stimulation systems for drug-resistant epilepsy and depression, and Cardiovascular, producing advanced cardiopulmonary bypass systems and heart-lung machine equipment. Its products are deployed in surgical operating rooms and hospital clinics worldwide to treat complex neurological and heart conditions. Revenue is derived directly from the sale of medical devices, surgical equipment, and proprietary implantable accessories to healthcare providers. LivaNova holds a leading global market position in neuromodulation therapy for epilepsy. The company is headquartered in London, United Kingdom, and its ordinary shares trade on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in LivaNova.
- Legal name
- LivaNova Plc
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 8
Funds holding LivaNova
- Simplicity Småbolag Global — Simplicity · 1.41 % (full portfolio disclosed, June 2026)
- Indecap Guide Global Offensiv — Indecap · 1.15 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.49 % (full portfolio disclosed, October 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.26 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.04 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.04 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- Nordea Internationale aktier — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)